Crossmark

International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy

Crossref DOI link: https://doi.org/10.1186/s12916-018-1007-9

Published Online: 2018-02-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beuscart, Jean-Baptiste https://orcid.org/0000-0002-0734-8371
Knol, Wilma

Cullinan, Shane

Schneider, Claudio

Dalleur, Olivia

Boland, Benoit

Thevelin, Stefanie

Jansen, Paul A. F.

O’Mahony, Denis

Rodondi, Nicolas

Spinewine, Anne
Funding

Funding for this research was provided by:

Horizon 2020 (6342388)
More Information

Article History

Received: 23 September 2017

Accepted: 17 January 2018

First Online: 13 February 2018

Ethics approval and consent to participate

: Ethical approval was obtained in Belgium (Comité d’Ethique Hospitalo-Facultaire, Cliniques Universitaires de Saint-Luc - UCL) and Ireland (Clinical Research Ethics Committee of the Cork Teaching Hospitals). In the Netherlands (Medical Ethics Review Committee UMC Utrecht) and Switzerland (Kantonale Ethikkommission Bern (KEK)), official ethical approval was not required, as the ethics committees confirmed that the relevant legislation was not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.